Virtual Library

Start Your Search

Li-Hua Qiu

Author of

  • +

    P3.01 - Advanced NSCLC (Not CME Accredited Session) (ID 967)

    • Event: WCLC 2018
    • Type: Poster Viewing in the Exhibit Hall
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 9/26/2018, 12:00 - 13:30, Exhibit Hall
    • +

      P3.01-48 - The Efficiency of Low-Dose ApatinibĀ in Treatment of Advanced Lung Squamous Cell Carcinoma (ID 12398)

      12:00 - 13:30  |  Author(s): Li-Hua Qiu

      • Abstract
      • Slides


      Chemotherapy is the main treatment for advanced lung squamous cell carcinoma(LSCC) patients due to lack of effective targeted agents. Previous studies proved that apatinib, which is an antiangiogenic and small-molecule targeted drug, showed clinical benefit in patients with advanced non-squamous non-small cell lung cancer. In this study, we assessed the efficacy and safety of low-dose (125mg or 250mg, QD, oral) apatinib in the treatment of advanced LSCC.

      a9ded1e5ce5d75814730bb4caaf49419 Method

      A total of 8 advanced LSCC patients clinical data were reviewed retrospectively including 1 patient treated only by apatinib and 7 patients combined with other anti-tumor therapies (i.e., bronchial artery embolization (BAE), chemotherapy, radiotherapy or surgery) between May 2016 to July 2017. Efficacy was evaluated with the RECIST version 1.1 and adverse effects (AEs) were graded using the NCI CTC version 4.0.

      4c3880bb027f159e801041b1021e88e8 Result

      One SD and 7 PR were confirmed, resulting in an objective response rate of 87.5% (7/8) and a disease control rate of 100% (8/8), respectively. The median progression-free survival (PFS) was 197 days (95% CI, 122-272 days), and the median overall survival (OS) was 252 days (95% CI,161-342 days). Both PFS and OS were 93 days for the patient with monotherapy, while the median PFS and median OS were 212 days (95% CI, 132-292 days) and 274 days (95% CI,182-366 days), respectively for the 7 patients with combined treatment. Patients with grade 3 or 4 AEs included 2 hemoptysis, 1 leukopenia and 1 fatigue. Patients characteristics are shown in the table below.table.jpg

      8eea62084ca7e541d918e823422bd82e Conclusion

      Low-dose apatinib combined with BAE, chemotherapy, radiotherapy or surgery is effective and well tolerated in advanced LSCC patients. Risk of massive hemoptysis should be considered in LSCC patients treated with apatinib alone. BAE or radiotherapy may play a role in the prevention and treatment of severe hemoptysis associated with apatinib.Further prospective studies with larger numbers of patients are required.


      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.